Statement of Principles concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma (Reasonable Hypothesis) (No. 78 of 2022)

Administered by Department of Veterans' Affairs

Legislation au F2022L01113 In force Legislative Instrument

Legislation content

EXPLANATORY STATEMENT

 

STATEMENT OF PRINCIPLES CONCERNING

MATURE B-CELL LYMPHOID LEUKAEMIA AND SMALL LYMPHOCYTIC LYMPHOMA

(REASONABLE HYPOTHESIS) (NO. 78 OF 2022)

 

VETERANS' ENTITLEMENTS ACT 1986

MILITARY REHABILITATION AND COMPENSATION ACT 2004

 

  1. This is the Explanatory Statement to the Statement of Principles concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma (Reasonable Hypothesis) (No. 78 of 2022).

Background

2.             The Repatriation Medical Authority (the Authority), under subsection 196B(8) of the Veterans' Entitlements Act 1986 (the VEA), repeals Instrument No. 84 of 2014 (Federal Register of Legislation No. F2014L01146) determined under subsections 196B(2) and (8) of the VEA concerning chronic lymphocytic leukaemia/small lymphocytic lymphoma.

3.             The Authority is of the view that there is sound medical-scientific evidence that indicates that mature B-cell lymphoid leukaemia and small lymphocytic lymphoma and death from mature B-cell lymphoid leukaemia and small lymphocytic lymphoma can be related to particular kinds of service.  The Authority has therefore determined pursuant to subsection 196B(2) of the VEA a Statement of Principles concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma (Reasonable Hypothesis) (No. 78 of 2022).  This Instrument will in effect replace the repealed Statement of Principles.

Purpose and Operation

4.             The Statement of Principles will be applied in determining claims under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).

5.             The Statement of Principles sets out the factors that must as a minimum exist, and which of those factors must be related to the following kinds of service rendered by a person:

 operational service under the VEA;

 peacekeeping service under the VEA;

 hazardous service under the VEA;

 British nuclear test defence service under the VEA;

 warlike service under the MRCA;

 non-warlike service under the MRCA,

before it can be said that a reasonable hypothesis has been raised connecting mature B-cell lymphoid leukaemia and small lymphocytic lymphoma or death from mature B-cell lymphoid leukaemia and small lymphocytic lymphoma, with the circumstances of that service.  The Statement of Principles has been determined for the purposes of both the VEA and the MRCA.

6.             This Instrument results from an investigation notified by the Authority in the Government Notices Gazette of 2 November 2021 concerning chronic lymphocytic leukaemia/small lymphocytic lymphoma.

7.             in accordance with section 196G of the VEA.  The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.

8.             The contents of this Instrument are in similar terms as the repealed Instrument.  Comparing this Instrument and the repealed Instrument, the differences include:

  • adopting the latest revised Instrument format, which commenced in 2015;
  • specifying a day of commencement for the Instrument in section 2;
  • including a definition of 'mature B-cell lymphoid leukaemia and small lymphocytic lymphoma' in subsection 7(2);
  • revising the factor in subsection 9(1) concerning being exposed to benzene as specified;
  • revising the factor in subsection 9(2) concerning being exposed to benzene;
  • revising the factor in subsection 9(3) concerning having chronic infection with hepatitis C virus;
  • new factor in subsection 9(4) concerning inhaling ethylene oxide vapour as specified;
  • new factor in subsection 9(5) concerning inhaling ethylene oxide vapour;
  • new factor in subsection 9(6) concerning having received a dose of ionising radiation to the bone marrow;
  • new factor in subsection 9(7) concerning inhaling 1,3 butadiene gas as specified;
  • new factor in subsection 9(8) concerning being exposed to 1,3-butadiene;
  • revising the definition of 'relevant service'; and
  • new definitions of 'chronic infection with hepatitis C', 'cumulative equivalent dose', 'inhaling 1,3 butadiene gas as specified', inhaling ethylene oxide vapour as specified, 'MRCA', 'ppm-years', VEA' in Schedule 1  Dictionary.

Consultation

9.             Prior to determining this Instrument, the Authority advertised its intention to undertake an investigation in relation to chronic lymphocytic leukaemia/small lymphocytic lymphoma in the Government Notices Gazette of 2 November 2021, and circulated a copy of the notice of intention to investigate to a wide range of organisations representing veterans, service personnel and their dependants.  The Authority invited submissions from the Repatriation Commission, the Military Rehabilitation and Compensation Commission, organisations and persons referred to in section 196E of the VEA, and any person having expertise in the field.  No submissions were received for consideration by the Authority in relation to the investigation.

Human Rights

10.         This instrument is compatible with the Human Rights and Freedoms recognised or declared in the International Instruments listed in Section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.  A Statement of Compatibility with Human Rights follows.

Finalisation of Investigation

11.         The determining of this Instrument finalises the investigation in relation to chronic lymphocytic leukaemia/small lymphocytic lymphoma as advertised in the Government Notices Gazette of 2 November 2021.

References

12.         A list of references relating to the above condition is available on the Authority's website at: www.rma.gov.au. Any other document referred to in this Statement of Principles is available on request to the Repatriation Medical Authority at the following address:

              

Email:    info@rma.gov.au

Post:      The Registrar

Repatriation Medical Authority

GPO Box 1014

BRISBANE    QLD    4001


Statement of Compatibility with Human Rights

(Prepared in accordance with Part 3 of the Human Rights (Parliamentary Scrutiny) Act 2011)

 

Instrument No.:   Statement of Principles No. 84 of 2020

Kind of Injury, Disease or Death: Mature B-cell lymphoid leukaemia and small lymphocytic lymphoma

 

This Legislative Instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the Human Rights (Parliamentary Scrutiny) Act 2011.

Overview of the Legislative Instrument

1. This Legislative Instrument is determined pursuant to subsection 196B(2) of the Veterans' Entitlements Act 1986 (the VEA) for the purposes of the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).  Part XIA of the VEA requires the determination of these instruments outlining the factors connecting particular kinds of injury, disease or death with service such being determined solely on the available sound medical-scientific evidence.

2. This Legislative Instrument:-

  • facilitates claimants in making, and the Repatriation Commission and the Military Rehabilitation and Compensation Commission in assessing, claims under the VEA and the MRCA respectively, by specifying the circumstances in which medical treatment and compensation can be extended to eligible persons who have mature B-cell lymphoid leukaemia and small lymphocytic lymphoma;
  • facilitates the review of such decisions by the Veterans' Review Board and the Administrative Appeals Tribunal;
  • outlines the factors which the current sound medical-scientific evidence indicates must as a minimum exist, before it can be said that a reasonable hypothesis has been raised, connecting mature B-cell lymphoid leukaemia and small lymphocytic lymphoma with the circumstances of eligible service rendered by a person, as set out in clause 5 of the Explanatory Statement;
  • replaces Instrument No. 84 of 2014; and
  • reflects developments in the available sound medical-scientific evidence concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma which have occurred since that earlier instrument was determined. 

3. The Instrument is assessed as being a technical instrument which improves the medico-scientific quality of outcomes under the VEA and the MRCA. 

Human Rights Implications

4. This Legislative Instrument does not derogate from any human rights. It promotes the human rights of veterans, current and former Defence Force members as well as other persons such as their dependents, including:

  • the right to social security (Art 9, International Covenant on Economic, Social and Cultural Rights; Art 26, Convention on the Rights of the Child and Art 28, Convention on the Rights of Persons with Disabilities) by helping to ensure that the qualifying conditions for the benefit are 'reasonable, proportionate and transparent'[1];
  • the right to an adequate standard of living (Art 11, ICESCR; Art 27, CRC and Art 28, CRPD) by facilitating the assessment and determination of social security benefits;
  • the right to the enjoyment of the highest attainable standard of physical and mental health (Art 12, ICESCR and Art 25, CRPD), by facilitating the assessment and determination of compensation and benefits in relation to the treatment and rehabilitation of veterans and Defence Force members;
  • the rights of persons with disabilities by facilitating the determination of claims relating to treatment and rehabilitation (Art 26, CRPD); and
  • ensuring that those rights "will be exercised without discrimination of any kind as to race, colour, sex, language, religion, political or other opinion, national or social origin, property, birth or other status" (Art 2, ICESCR).

Conclusion

This Legislative Instrument is compatible with human rights as it does not derogate from and promotes a number of human rights.

 

Repatriation Medical Authority

 

 

 

 

 

[1] In General Comment No. 19 (The right to social security), the Committee on Economic, Social and Cultural Rights said (at paragraph 24) this to be one of the elements of ensuring accessibility to social security.

Overview

The Statement of Principles concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma (Reasonable Hypothesis) (No. 78 of 2022) was enacted to address the problem of determining the connection between mature B-cell lymphoid leukaemia, small lymphocytic lymphoma, and various types of military service, including operational, peacekeeping, and hazardous service, under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. The Repatriation Medical Authority, exercising its powers under subsection 196B(2) of the Veterans' Entitlements Act, repealed the previous Instrument No. 84 of 2014 and introduced this new statement of principles, following an investigation into the medical-scientific evidence relating to these conditions. This legislative instrument facilitates the claims process for veterans and service personnel by clearly outlining the factors that must be present to establish a reasonable hypothesis connecting these diseases with military service, thereby ensuring that eligible individuals can access appropriate medical treatment and compensation. The instrument, which is compatible with human rights as outlined in the Human Rights (Parliamentary Scrutiny) Act 2011, promotes the rights of veterans and service personnel, including the right to social security and to an adequate standard of living, while ensuring non-discriminatory access to benefits. This new statement of principles replaces the previous one and reflects the latest medical-scientific evidence, ensuring that the claims process remains fair and evidence-based.

Scope and Application

The Statement of Principles concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma (Reasonable Hypothesis) (No. 78 of 2022) applies to veterans, current and former members of the Australian Defence Force, and their dependants who are seeking benefits under the Veterans' Entitlements Act 1986 (VEA) and the Military Rehabilitation and Compensation Act 2004 (MRCA). It specifies the medical conditions and service-related circumstances that must exist for a reasonable hypothesis to be raised connecting mature B-cell lymphoid leukaemia and small lymphocytic lymphoma or death from these conditions with the service rendered by a person. This legislative instrument is determined by the Repatriation Medical Authority under subsection 196B(2) of the VEA and applies nationally across Australia. The Instrument does not contain specific exclusions or exemptions, but the factors outlined must be related to the types of service mentioned in the legislation. The application of the Act may be extended or restricted through subordinate instruments, but no such provisions are specified in the text. The legislative instrument is compatible with human rights, as it does not derogate from any human rights and promotes several rights, including the right to social security, adequate standard of living, and highest attainable standard of physical and mental health.

Key Provisions

The Statement of Principles concerning mature B-cell lymphoid leukaemia and small lymphocytic lymphoma (Reasonable Hypothesis) (No. 78 of 2022) sets out the factors that must be present to establish a reasonable hypothesis that the disease is connected to particular kinds of military service (section 5). This is determined under subsection 196B(2) of the Veterans' Entitlements Act 1986 (VEA) and applies to claims under both the VEA and the Military Rehabilitation and Compensation Act 2004 (MRCA). The service types include operational, peacekeeping, hazardous, and British nuclear test defence service under the VEA, and warlike and non-warlike service under the MRCA. The determination is based on sound medical-scientific evidence and replaces the previous Statement of Principles No. 84 of 2014. The Statement of Principles imposes obligations on claimants to provide evidence that the factors specified in the document are related to their service, ensuring that claims are substantiated by medical-scientific evidence. It also places the onus on the Repatriation Commission and the Military Rehabilitation and Compensation Commission to assess claims using these specified factors. The Statement of Principles facilitates the review of decisions by the Veterans' Review Board and the Administrative Appeals Tribunal. Breach of the requirements set out in the Statement of Principles could lead to the rejection of a claim for compensation or medical treatment. The VEA and MRCA provide for various civil and administrative consequences for non-compliance, including the right to appeal decisions made under these Acts. However, the Statement of Principles itself does not specify penalties for non-compliance, as it operates within the broader legislative frameworks of the VEA and MRCA. The Statement of Principles is compatible with human rights, as outlined in the Statement of Compatibility with Human Rights. It ensures that the right to social security, an adequate standard of living, and the highest attainable standard of physical and mental health are facilitated for veterans and Defence Force members. It also ensures that these rights are exercised without discrimination, promoting equality and non-discrimination in the assessment and determination of claims.

Legal classification tags

Area of Law
Veterans' Law
Instrument
Act
Concepts
Definitions & Interpretation
Offence Provisions
Reporting & Disclosure Obligations

Interactions

Authorises

All Versions

Sourced from the Federal Register of Legislation at 26 August 2026. For the latest information on Australian Government law please go to https://www.legislation.gov.au.